Search Results - "Sendilnathan, Arun"

Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: A Century-Long Story by Naffouje, Rand, Grover, Punita, Yu, Hongyang, Sendilnathan, Arun, Wolfe, Kara, Majd, Nazanin, Smith, Eric P, Takeuchi, Koh, Senda, Toshiya, Kofuji, Satoshi, Sasaki, Atsuo T

“…The purine nucleotides ATP and GTP are essential precursors to DNA and RNA synthesis and fundamental for energy metabolism. Although de novo purine nucleotide…”
Get full text

Decreased plasma DEK Oncogene Levels Correlate with p16-Negative Disease and Advanced Tumor Stage in a Case–Control Study of Patients with Head and Neck Squamous Cell Carcinoma by Wise-Draper, Trisha, Sendilnathan, Arun, Palackdharry, Sarah, Pease, Nicholas, Qualtieri, Julianne, Butler, Randall, Sadraei, Nooshin Hashemi, Morris, John C., Patil, Yash, Wilson, Keith, Mark, Jonathan, Casper, Keith, Takiar, Vinita, Lane, Adam, Privette Vinnedge, Lisa

“…Head and neck cancer (HNC) remains the sixth most common malignancy worldwide and survival upon recurrence and/or metastasis remains poor. HNSCC has…”
Get full text

Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2 by Gill, David M, Stenehjem, David D, Parikh, Kinjal, Merriman, Joseph, Sendilnathan, Arun, Agarwal, Archana M, Hahn, Andrew W, Gupta, Sumati, Tantravahi, Srinivas Kiran, Samlowski, Wolfram E, Agarwal, Neeraj

“…Conditional survival (CS) is a clinically useful prediction measure which adjusts a patient's prognosis based on their duration of survival since initiation of…”
Get full text

Abstract 584: The DEK oncogene may serve as a predictive plasma biomarker in head and neck cancer patients by Wise-Draper, Trisha, Privette Vinnedge, Lisa, Sendilnathan, Arun

“…Abstract Head and neck cancer (HNC) remains the sixth most common cancer worldwide with almost 50,000 new diagnoses in the US each year. Although, infection…”
Get full text

How anti-c in a D- patient prompted lifesaving work between a transfusion service and a blood center reference laboratory by Patch, Gavin, Maurer, Joan, Sendilnathan, Arun, Leak, Christine, Nartowicz, Elizabeth, Kavitsky, Victoria, Facey, Dexter, Nance, Sandra T, Keller, Margaret A

“…This case report showcases an extraordinary collaboration to support the transfusion needs of a patient with a rare phenotype and long-standing anemia due to…”
Get more information

Advanced biliary tract cancer: Experience with ABC-02 regimen in a tertiary care center in the United States by Agarwal, Rishi, Siddiqi, Nabeela Iffat, Gulati, Shuchi, Sendilnathan, Arun, Xie, Changchun, Olowokure, Olugbenga Olanrele

“…Abstract only…”
Get full text

Investigation of IMPDH2 overexpression in renal cell carcinoma (RCC) & its association with oncologic outcomes by Sendilnathan, Arun, Velagapudi, Ramya Krishna, Marinos Velarde, Alejandro, Jandarov, Roman, Zhu, Zheng, Randhawa, Jaskirat Singh, Dillehay McKillip, Kelsey, Yoshino, Hirofumi, Kofuji, Satoshi, Okumura, Koichi, Naffouje, Rand, Koch, Matthew, Ao, Xiang, Finley, Kara, Sasaki, Atsuo

“…Abstract only 594 Background: Approximately 40% of locoregional RCC patients relapse after nephrectomy leading to lower 5 year survival rates of 53% (stage…”
Get full text

Impact of pre-treatment absolute lymphocyte count, absolute monocyte count and their ratio on survival in diffuse large B cell lymphoma by Deeb, Ayham, Yellu, Mahender, Latif, Tahir, Guha, Gunjan, Sendilnathan, Arun, Ghose, Abhimanyu, Medlin, Stephen Charles

“…Abstract only…”
Get full text

Abstract 50: Plasma concentrations of the DEK oncogene correlate with pathological variables in a case-control study of patients with HNSCC by Wise-Draper, Trisha, Sendilnathan, Arun, Palackdharry, Sarah, Pease, Nicholas, Qualtieri, Julianne, Butler, Randy, Sadraei, Nooshin Hashemi, Morris, John C., Patil, Yash, Wilson, Keith, Mark, Jonathan, Casper, Keith, Takiar, Vinita, Lane, Adam, Vinnedge, Lisa M. Privette

“…Abstract Background: Head and neck squamous cell carcinoma (HNSCC) has traditionally been associated with alcohol and nicotine use, but more recently the Human…”
Get full text

Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States by Agarwal, Rishi, Sendilnathan, Arun, Siddiqi, Nabeela Iffat, Gulati, Shuchi, Ghose, Abhimanyu, Xie, Changchun, Olowokure, Olugbenga Olanrele

“…Gemcitabine plus cisplatin (GC) is currently the standard regimen for advanced biliary tract cancers (BTC) based on the outcomes in ABC-02 trial. Multiple…”
Get full text

Low-Dose Cyclophosphamide Plus Granulocyte Colony-Stimulating Factor As an Efficacious and Safe Peripheral Blood Stem Cell Mobilizing Regimen in Patients with Hematologic Malignancies by Sendilnathan, Arun, Randhawa, Jaskirat Singh, Xie, Changchun, Bolt, Rebecca, Leemhuis, Thomas, Buzek, Nora, Tierney, Kitty, Pinkard, Susan, Girnius, Saulius, Medlin, Stephen

“…▪ Introduction: Collection of adequate numbers of Hematopoietic Stem Cells (HSCs) is a prerequisite for proceeding to autologous bone marrow transplant…”
Get full text

Abstract A51: Investigation of the DEK oncogene as a blood biomarker for breast cancer by Sendilnathan, Arun, Charif, Mahmoud, Shaughnessy, Elizabeth, Lewis, Jaime D., Radhakrishnan, Neetu, Lower, Elyse, Lanigan, Catherine, Kumar, Harriet, Wise-Draper, Trisha M., Vinnedge, Lisa Privette

“…Abstract Breast cancer (BC) is one of the leading causes of death for women in the United States. This is due, in part, because women wait too long to get a…”
Get full text

Lymphopenia as a predictor of survival in chemoradiation (CRT)-treated stage III non-small cell lung cancer (NSCLC) by Yellu, Mahender, Fakhrejahani, Farhad, Ying, Jun, Mierzwa, Michelle, Malek, Ehsan, Haque, Sulsal, Sendilnathan, Arun, Huth, Bradley Joseph, Morris, John Charles, Abdel Karim, Nagla, Latif, Tahir, Redmond, Kevin P., Barrett, William, Videtic, Gregory M.M., Hashemi Sadraei, Nooshin

“…Abstract only…”
Get full text

Association of quality of life (QOL) with oncologic and functional outcomes in head and neck cancer (HNC) patients (pts) by Sendilnathan, Arun, Agarwal, Rishi, Deeb, Ayham, Bach, Robert, Xie, Changchun, Kaval, Farah, Robinson, Courtney, Guthrie, Kelly, Wise-Draper, Trisha Michel, Morris, John Charles, Mierzwa, Michelle Lynn, Huth, Bradley Joseph, Redmond, Kevin P., Barrett, William, Patil, Yash, Wilson, Keith, Adelstein, David J., Casper, Keith, Hashemi Sadraei, Nooshin

“…Abstract only…”
Get full text

Conditional survival (CS) of metastatic renal cell carcinoma (mRCC) patients treated with high-dose interleukin-2 (HD IL-2) by Straubhar, Alli M., Stenehjem, David D., Parikh, Kinjal, Merriman, Joseph, Crispin, Hilda, Sendilnathan, Arun, Van Atta, Joan, Batten, Julia A., Agarwal, Archana M., Tantravahi, Srinivas Kiran, Samlowski, Wolfram E., Agarwal, Neeraj

“…Abstract only…”
Get full text

Correlation of stable disease (SD) as best response with survival outcomes in patients (pts) with clear cell (cc) metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2) by Merriman, Joseph, Parikh, Kinjal, Tantravahi, Srinivas Kiran, Straubhar, Alli M., Agarwal, Archana M., Sendilnathan, Arun, Van Atta, Joan, Batten, Julia A., Grossmann, Kenneth F., Samlowski, Wolfram E., Stenehjem, David D., Agarwal, Neeraj

“…Abstract only…”
Get full text

Quality of life (QOL) as a predictor of clinical outcome in patients (pts) with head and neck cancer (HNC) by Sendilnathan, Arun, Deeb, Ayham, Bach, Robert, Agarwal, Rishi, Xie, Changchun, Kaval, Farah, Robinson, Courtney, Guthrie, Kelly, Dupuy, Sue, Wise-Draper, Trisha Michel, Morris, John Charles, Mierzwa, Michelle Lynn, Huth, Bradley Joseph, Redmond, Kevin P., Barrett, William, Patil, Yash, Wilson, Keith, Adelstein, David J., Casper, Keith, Hashemi Sadraei, Nooshin

“…Abstract only…”
Get full text

Association between rigors and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose interleukin-2 (HD IL-2) by Batten, Julia Anne, Samlowski, Wolfram E., Parikh, Kinjal, Sendilnathan, Arun, Crispin, Hilda, Van Atta, Joan, Sageser, Daniel, Grossmann, Kenneth F., Wang, Junfeng, Tantravahi, Srinivas Kiran, Stenehjem, David D., Agarwal, Neeraj

“…Abstract only 487 Background: HD IL-2 is associated with an objective response rate of 16-20% with durability of response in select mRCC patients. HD IL-2 is…”
Get full text

Conditional survival (CS) of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD IL-2) by Parikh, Kinjal, Stenehjem, David D., Sendilnathan, Arun, Crispin, Hilda, Van Atta, Joan, Batten, Julia Anne, Sageser, Daniel, Grossmann, Kenneth F., Wang, Junfeng, Samlowski, Wolfram E., Tantravahi, Srinivas Kiran, Agarwal, Neeraj

“…Abstract only 460 Background: CS is a clinically useful prediction measure that adjusts prognosis of patients on the basis of survival since treatment…”
Get full text

Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma by Lam, Elaine T, Wong, Michael K K, Agarwal, Neeraj, Redman, Bruce G, Logan, Theodore, Gao, Dexiang, Flaig, Thomas W, Lewis, Karl, Poust, Jamie, Monk, Paul, Jarkowski, Anthony, Sendilnathan, Arun, Bolden, Marcus, Kuzel, Timothy M, Olencki, Thomas

“…Although tyrosine kinase inhibitors (TKI) are the most common first-line therapy for metastatic renal cell carcinoma, high-dose interleukin-2 (HD-IL2) remains…”
Get full text